Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Short-term Investments: 2015-2022

Historic Short-term Investments for Cartesian Therapeutics (RNAC) over the last 6 years, with Dec 2022 value amounting to $28.2 million.

  • Cartesian Therapeutics' Short-term Investments rose 101.20% to $28.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $28.2 million, marking a year-over-year increase of 101.20%. This contributed to the annual value of $28.2 million for FY2022, which is 101.20% up from last year.
  • Cartesian Therapeutics' Short-term Investments amounted to $28.2 million in FY2022, which was up 101.20% from $14.0 million recorded in FY2021.
  • In the past 5 years, Cartesian Therapeutics' Short-term Investments ranged from a high of $28.2 million in FY2022 and a low of $279,000 during FY2019.
  • Its 2-year average for Short-term Investments is $21.1 million, with a median of $21.1 million in 2021.
  • Data for Cartesian Therapeutics' Short-term Investments shows a peak YoY soared of 101.20% (in 2022) over the last 5 years.
  • Cartesian Therapeutics' Short-term Investments (Yearly) stood at $279,000 in 2019, then reached $14.0 million in 2021, then skyrocketed by 101.20% to $28.2 million in 2022.